The investment was led by Cenitz with participation from KIMA Ventures, Advans Lab, and Bpifrance, along with support from doctors, health insurance angels, and business leaders from Implicity, Deepmind, and Nabla. Frederic Picq, the co-founder at Cenitz, says, “Our investment in Metyos was driven by its impressive founding team, a clear and growing market need, and the life-changing potential of its technology.” “Alex and Olga bring a blend of entrepreneurial spirit and technical expertise that is rare and invaluable in the medtech space. With CKD affecting 10 per cent of the population and being a major cause of death, Metyos seeks to proactively manage symptoms and slow disease progression, benefiting both patients and healthcare systems. Metyos, founded by CEO Alexandre Boulanger and CTO Olga Chashchina, aims to transform the lives of over 800 million CKD patients globally. Co-founder Boulanger says, “Our mission at Metyos is to move healthcare away from reactive care towards proactive disease management.” “A healthcare future where millions of CKD patients are empowered to take control of their health, and where they can access life-saving early detection and personalised interventions.” “This funding, and the support and belief of the brilliant investors it brings with it, will help make this future a reality and help change the lives of so many patients and medical professionals worldwide.”